Browse Studies About FAQ

Sign in Get started

Match. Apply. Get paid. The simplest way to participate in paid clinical research.

Product

Browse Studies How it Works Verification Arctuva Pro For Sponsors

Company

About Contact FAQ

Legal

Privacy Terms of Service Security Accessibility Transparency Report

© 2026 Arctuva, Inc. All rights reserved.

Compensation is for time and inconvenience, not income.

Browse Studies — Arctuva | Arctuva

Browse studies

Find your next paid study

3 recruiting studies matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.

IvonescimabClear Cell Renal Carcinoma

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06940518

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments…

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)

~$10 – $5,625

National Cancer Institute (NCI)NCT05665361

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma…

Clear Cell Renal Cell Cancer (ccRCC)Clear Cell Renal CarcinomaClear Cell Renal Cell Carcinoma Metastatic+7 more

~$10 – $7,500

Kelly Fitzgerald, MDNCT07043608